Mutation_analysis_of COL1A1 and COL1A2 in_patients with Osteogenesis Imperfecta


https://pubmed.ncbi.nlm.nih.gov/25633413/


This research paper looks at the genetic causes of osteogenesis imperfecta (OI), a condition known for fragile bones and frequent fractures. OI can range from mild to life-threatening, and people with the condition can be affected very differently—even within the same family. The researchers focused on two genes, COL1A1 and COL1A2, which are responsible for making type I collagen. Type I collagen is a key building block of bone, and problems in these genes are known to cause most cases of OI types I through IV.


The study examined 83 unrelated patients who had been diagnosed with OI. Using detailed genetic testing, the researchers searched for changes (mutations) in the COL1A1 and COL1A2 genes. They found 62 different mutations, many of which had never been reported before. About three-quarters of the patients had a detectable mutation using this testing method, and the success rate was even higher for patients with a clear clinical diagnosis of OI.

Most of the mutations affected a very specific part of the collagen molecule where the structure depends on a repeating pattern that includes the amino acid glycine. When glycine is replaced by another building block, the collagen can fold incorrectly, leading to weaker bones. These changes were often linked to more severe forms of OI. Other types of mutations reduced the amount of normal collagen produced, which tended to cause milder disease. The study also identified rare and unusual mutations that affect how collagen is processed inside cells, showing that OI can result from multiple biological mechanisms—not just one.

An important finding was that the same type of genetic change does not always cause the same severity of OI. Some patients with similar mutations had very different symptoms. In a small number of cases, patients had more than one genetic change that might influence how severe their OI became. This highlights why predicting outcomes in OI based on genetics alone can be difficult.

Overall, this study adds significantly to the understanding of why OI varies so much from person to person. It also shows that comprehensive genetic testing can help confirm a diagnosis, clarify inheritance patterns, and improve genetic counseling for families affected by OI.


In summary...


This study helps explain why osteogenesis imperfecta can look so different from one person to another by identifying many new genetic changes linked to the condition. By improving our understanding of how collagen genes affect bone strength, the research supports more accurate diagnosis and better genetic counseling for families living with OI. While it does not introduce a new treatment, it lays important groundwork for future research and more personalized care for people with brittle bone disease.



Osteogenesis imperfecta, diffuse idiopathic skeletal hyperostosis, and hypophosphatasia one year in review 2025


ORIG PUB: External link opens in new tab or window https://pubmed.ncbi.nlm.nih.gov/40631423/


This summary draws from the second source provided, titled "One Year in Review 2025," which provides a modern update on the classification, clinical challenges, and treatment of Osteogenesis Imperfecta (OI).

A Modern Look at OI: Classification and New Discoveries

The sources explain that OI is primarily a genetic disorder affecting type I collagen, which makes up 90% of our bone matrix. While we have known about the "Sillence types" (1–5) for decades, doctors are moving toward a "dyadic nosology." This means they now use a two-part system that combines a patient's clinical symptoms (like bone fragility or blue sclera) with their genetic mutation (types I–XXIII). This change is necessary because people in the same family with the same mutation can have very different levels of severity.

Broadening the Focus: It’s More Than Just Bones

New research from 2024–2025 highlights that OI affects the entire body, not just the skeleton:

• Hearing Loss: A large study found that hearing loss is much more common in OI patients (17%) than in the general population (4%) and typically starts about 16 years earlier, often around age 42.

• Heart Health: While there are no formal guidelines yet, researchers suggest all OI patients get a baseline echocardiogram to check for heart valve issues, especially if they have joint hypermobility.

• Dental Issues: Between 20% and 48% of patients have Dentinogenesis Imperfecta (fragile, discolored teeth), and many deal with "Class III" malocclusions (underbites).

• Eye Health: To help doctors more accurately identify "blue sclera," a new computer-based procedure called "BLUES" has been developed to objectively measure the color of the eye.

The Evolving Treatment Landscape

For years, bisphosphonates like neridronate and zoledronate have been the "cornerstone" of treatment to improve bone density. However, the sources point to an exciting new era of targeted therapies:

• Denosumab: This is a strong alternative to bisphosphonates, though doctors must watch for rebound high calcium levels in children.

• Setrusumab: A new antibody that has shown great promise in adults by significantly increasing bone density in the spine and hips.

• Future Frontiers: Trials are currently exploring stem cell transplants (MSC) for infants and new antibodies that target specific growth factors (TGF-β) to improve bone quality.

--------------------------------------------------------------------------------

What this may mean for OI Patients


For those living with OI, this recent research signals a shift toward "whole-body" care. It suggests that managing the condition is no longer just about preventing fractures; it now requires regular hearing tests, dental checkups, and heart screenings started much earlier in life than for the average person. The move toward a more detailed classification system means your doctor can provide a more personalized roadmap for your health. Most importantly, the arrival of new drugs like setrusumab and the study of stem cell therapies offer hope for treatments that don't just "patch" the bone but actually improve its underlying structure and strength.


To visualize this shift, think of OI care as moving from fixing a leaky roof (treating fractures) to a comprehensive home inspection (monitoring the heart, ears, and eyes) while using next-generation building materials (new targeted drugs) to reinforce the entire foundation.


Click to edit text. What do visitors to your website need to know about you and your business?



A Genetic Snapshot of OI in Estonia


Osteogenesis Imperfecta (OI) is a rare condition that makes bones incredibly fragile and can lead to issues like blue eye sclera, hearing loss, and short stature. While many genes are involved in bone health, about 90% of OI cases globally stem from mutations in the COL1A1 and COL1A2 genes, which provide the instructions for building Type I collagen. Because Estonia has a small population, researchers were able to study 30 unrelated families, which they believe accounts for nearly 100% of the OI cases in the entire country.

The study found that 86.67% of these patients carried a mutation in one of those two main collagen genes. Interestingly, the genetic landscape in Estonia looks very similar to its neighbors, Sweden and Finland. However, the researchers discovered that half of the mutations they found were "novel," meaning they were completely new to the international databases used by scientists. This shows that even within a small population, the genetic causes of OI can be incredibly diverse and unique to specific families.

Quantity vs. Quality: Two Ways Collagen Fails

The researchers categorized the mutations into two main groups based on how they messed up the body’s collagen production:

• Quantitative Defects (The "Not Enough" Problem): About 69% of the patients had mutations that caused their bodies to produce too little collagen. These are often considered "milder" because the collagen that is produced is normal, there just isn't enough of it.

• Qualitative Defects (The "Bad Quality" Problem): Roughly 31% had mutations that changed the actual structure of the collagen. The most common error here was a "missense" mutation, where a single amino acid (usually Glycine) was swapped for another (usually Serine).

One of the most surprising findings involved two patients who had the exact same genetic mutation but very different lives. One patient had Type I OI (the mildest form), while the other had Type III (a much more severe form). This suggests that genetics isn't everything; other factors like a person's environment or "epigenetics" (how genes are turned on and off) play a huge role in how the disease actually looks.

To visualize this, think of collagen as the wooden studs in the frame of a house. A quantitative defect is like building a house with only half the number of studs it needs—the house is standing, but it's dangerously weak. A qualitative defect is like having all the studs you need, but the wood is full of knots and cracks; even if you use the right amount, the structure is prone to snapping under pressure.


What this may mean for OI Patients

This research highlights that having a specific mutation doesn't necessarily predict a person’s exact "destiny" or severity of symptoms. Because the same mutation can lead to different levels of bone fragility, it gives hope that there may be other biological "protective factors" we don't fully understand yet. Furthermore, the high rate of novel mutations discovered in this study proves that personalized genetic testing is vital. As more families get tested, the global library of mutations grows, helping doctors provide more accurate diagnoses and moving us closer to treatments that can address the specific "quantity" or "quality" issues in a patient's collagen